The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagdish Umakant Nayak, Promoter and Managing Director of Clinitech Laboratory Ltd, along with Persons Acting in Concert (family members), purchased 4,800 equity shares through the open market across two days — 2,400 shares on 17/03/2026 and 2,400 shares on 18/03/2026. The acquisition raised the promoter group's combined holding from 14,51,000 shares (63.57%) to 14,55,800 shares (63.78%), an increase of 0.21%. The total share capital of the company remained unchanged at 22,82,400 shares. The disclosure was filed under Regulation 29(2) of the SEBI Takeover Regulations, 2011.
This is a small open-market purchase by the promoter group, signalling continued insider confidence, but the size is marginal and unlikely to materially move the stock price. Promoter holding remains comfortably above 50%, so there is no change in control or near-threshold concern.